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CD1 proteins are a family of cell surface molecules
that present lipid antigens to T cells. We investigated
skin dendritic cells and monocyte-derived dendritic
cells for expression of CD1 molecules using a panel
of 10 different monoclonal antibodies focusing on
the recently described CD1d molecule. By immuno-
histochemical analysis, CD1d expression in normal
human skin was restricted to dendritic appearing
cells in the papillary dermis mainly located in a peri-
vascular localization. Langerhans cells did not show
detectable CD1d expression in situ. Epidermal/der-
mal cell suspensions analyzed by ¯ow cytometry
demonstrated distinct subpopulations of HLA-DR
positive dermal dendritic cells expressing CD1a,
CD1b, and CD1c. CD1d was expressed on HLA-
DRbright dermal antigen-presenting cells in dermal
suspensions (16% 6 3.6%), as well as on highly
enriched dermal dendritic cells migrating out of skin
explants (60.5% 6 8.0%). Migrated mature dermal
dendritic cells coexpressed CD83 and CD1d. Western
blot analysis on microdissected skin sections revealed
the presence of a 50±55 kDa CD1d molecule in der-
mis, suggesting that CD1d is highly glycosylated in
skin. Both immature and mature monocyte-derived
dendritic cells cultured in autologous plasma
expressed CD1d molecules. In contrast, culture in
fetal bovine serum downregulated CD1d expression.
In conclusion, antigen-presenting cells in skin
express different sets of CD1 molecules including
CD1d and might play a role in lipid antigen presen-
tation in various skin diseases. Differential expression
of CD1 molecules depending on culture conditions
might have an impact on clinical applications of den-
dritic cells for immunotherapy. Key words: antigen-
presenting cells/CD1molecules/glycolipids/Langerhans cells/
lipids. J Invest Dermatol 117:576±582, 2001
D
endritic cells are professional antigen-presenting cells
(APC) specialized for initiation of primary immune
responses. Dendritic APC capture, process, and
®nally present protein antigens in the form of
peptide major histocompatibility complexes
(MHC) to effector T cells. For this purpose dendritic cells are
well equipped with MHC, adhesion, and costimulatory molecules
(Cella et al, 1997; Banchereau and Steinman, 1998). Recently,
several studies have identi®ed a nonclassical antigen-presenting
pathway involving molecules of the CD1 family of surface proteins
(Balk et al, 1989; Blumberg et al, 1991; Porcelli et al, 1998; Porcelli
and Modlin, 1999). In contrast to MHC molecules CD1 proteins
are nonpolymorphic and are able to present lipids and glycolipids to
T cells generating a speci®c cell mediated immune response (Grant
et al, 1999; Rosat et al, 1999). CD1-restricted T cells play a crucial
role in immune responses against mycobacteria (Sieling et al, 1999;
Stenger and Modlin, 1999) and tumors (Cui et al, 1997; Kawano et
al, 1998; 1999; Toura et al, 1999). The CD1 family is divided in
two groups on the basis of biochemical and functional similarities.
Group I includes CD1a, CD1b, and CD1c proteins, whereas group
II includes CD1d (Balk et al, 1989; Yu and Milstein, 1989). It has
been demonstrated that the CD1d molecule enables cells to interact
with natural killer T cells, a subset of lymphocytes able to produce
high levels of interleukin-4 (IL-4) and interferon-g (IFN-g) upon
stimulation (Exley et al, 1997; Kawano et al, 1997; Brossay et al,
1998a, b; Exley et al, 1998). Although numerous studies have been
carried out on the expression of group I CD1 molecules in skin
(Furue et al, 1992; Elder et al, 1993; Meunier et al, 1993, 1996;
Nestle et al, 1993; Fivenson and Nickoloff, 1995; Larregina et al,
1997) and monocyte-derived dendritic cells (mo-DC) (Kasinrerk et
al, 1993), few data are available on the expression of CD1d by skin
APC in humans (Bonish et al, 2000). The aim of this study was
therefore to investigate the expression of CD1 molecules on skin
APC, focusing in particular on CD1d. We extended our
investigation also to mo-DC, as these cells are classical in vitro
models for immature and mature dendritic cells. Furthermore, mo-
DC are increasingly used for immunotherapy of cancer such as
melanoma (Nestle et al, 1998).
Here we show that in normal human skin dermal dendritic cells
(DDC) both in vivo and in vitro express all members of the CD1
family, including CD1d. CD1d expression on mo-DC was
in¯uenced by the presence of culture factors such as autologous
plasma (AP) or fetal bovine serum (FBS). In the presence of AP
immature and mature mo-DC expressed CD1d, whereas down-
regulation of this molecule was induced by FBS. Thus mo-DC and
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DDC express surface molecules that facilitate the presentation of
lipids and glycolipids and potential cross-talk with natural killer T
cells.
MATERIALS AND METHODS
Reagents and antibodies RPMI 1640 (Life Technologies, Eggenstain,
Germany) and X VIVO 15 (BioWhittaker, Belgium) were supplemented
with 1% penicillin/streptomycin (Gibco, Basel, Switzerland), 2%
glutamin (Seromed, Berlin, Germany), and 10% heat-inactivated FBS. In
some experiments FBS was replaced by 1% heat-inactivated (45 min at
56°C) AP. The following monoclonal (MoAb) or polyclonal antibodies
were used: CD1a PE and CD1a (NA1/34, IgG2a) from Dako (Glostrup,
Denmark); CD1b FITC (M-T101, IgG1) and CD86 FITC (2331
FUN-1, IgG1) from Pharmingen (San Diego, CA); CD1b (BCD1b3.1.6,
IgG1) kindly provided by Dr. S.A. Porcelli; CD1c (L161, IgG1) and
CD83 PE (HB15a, IgG2b) from Immunotech (Marseilles, France);
CD1d (42.1, IgG1; D5, IgG2b; 51.1.3, IgG2b; 27.1, IgG1; rabbit anti-
CD1d) kindly provided by Dr. S.P. Balk; CD1d (NOR3.2, IgG1) from
Biosource International (Camarillo, CA); HLA-DR FITC, HLA-DR PE
(L243, IgG2a), and CD80 PE (L307.4, IgG1) from Becton Dickinson
(Mountain View, CA). Goat antimouse phycoerythrin (PE) and
¯uorescein isothiocyanate (FITC) from Dako were used as secondary
antibodies for ¯ow cytometry. Goat antimouse conjugated with Texas
Red (Southern Biotechnology Associates, Birmingham, AL) was used for
immuno¯uorescence staining.
Generation of mo-DC Peripheral blood mononuclear cells were
obtained from buffy coats by Ficoll-Paque gradient (Amersham
Pharmacia Biotech, Uppsala, Sweden) and frozen in 90% FBS and 10%
dimethylsulfoxide until use. Dendritic cells were generated from
peripheral blood mononuclear cells as previously described with minor
modi®cations (Cella et al, 1997; Jonuleit et al, 1997; Nestle et al, 1998).
Brie¯y, 50 3 106 peripheral blood mononuclear cells were thawed and
cultured in 10 cm diameter Petri dishes (Falcon-Becton Dickinson,
Franklin Lakes, NJ) in complete RPMI with either 1% AP or 10% FBS
for 30±45 min. After removing the ¯oating cells and washing with
phosphate-buffered saline (PBS) the adherent cells were cultured
overnight in complete RPMI. The following day RPMI was removed
and replaced with X VIVO 15 supplemented with 800 U per ml
granulocyte macrophage colony stimulating factor (GM-CSF; Leucomax,
Sandoz-Wander Pharma, Bern) and 1000 U per ml IL-4 (R&D System,
Europe). At days 3 and 5 fresh medium supplemented with the cytokines
was added. At day 6 the cells were stimulated with a maturation
cytokine cocktail including tumor necrosis factor a (TNF-a) (10 ng per
ml), IL-6 (1000 U per ml), and IL-1b (10 ng per ml) (R&D System,
Europe). Cells were analyzed at different maturation days by ¯ow
cytometry.
Isolation of skin dendritic cells Skin dendritic cells were obtained
from normal human skin tissue belonging to healthy patients undergoing
breast reduction. The skin was incubated in Dispase type 2 (Boehringer-
Mannheim, Mannheim, Germany) and RPMI 1:1. After 1 h at 37°C
epidermis was separated from dermis, washed three times with PBS, and
cut in small pieces (1±10 mm). A portion of the epidermal and dermal
sheets was cultured in RPMI supplemented with 10% FBS for 2 d in
order to allow the cells to migrate out as described previously (Nestle
et al, 1993). The remaining epidermal sheets were incubated with trypsin
(Biochrom, Berlin, Germany), whereas the dermal sheets were incubated
with an enzyme cocktail consisting of collagenase, hyaluronidase (Sigma-
Chemie, Switzerland), and DNAse (Boehringer-Mannheim, Mannheim,
Germany) for 1 h at 37°C on a shaker in order to obtain a cell
suspension. Fresh epidermal and dermal suspensions were either
immediately analyzed by ¯uorescence-activated cell sorter (FACS)
analysis or cultured for 2 d in RPMI supplemented with 10% FBS,
1000 U per ml IL-4, and 800 U per ml GM-CSF. After 2 d both
migrated cells and cells in suspension were collected and used for FACS
analysis. In addition cytospins (Shandon, Pittsburgh, PA) were also
prepared using the migrated cells.
Immunohistochemistry Biopsy samples of normal skin (N = 10)
were chosen from the cryopreserved tissue archived in the Department
of Dermatology of Zurich. Representative 5±7 mm serial cryostat
Figure 1. Expression of CD1 molecules,
including CD1d, on skin dendritic APC.
Representative immunohistochemical staining of
normal skin. (a) Epidermal dendritic cells and
DDC (arrow) stained with anti-CD1a (NA1/34).
(b)±(d) Dendritic dermal APC express CD1b (b,
BCD1b3.1.6), CD1c (c, L161), and CD1d (d,
polyclonal rabbit antibody). (e)±( f ) A subset of
cultivated DDC express CD1d. Immuno-
histochemical staining of migrated DDC using
anti-CD1d antibody (e, 51.1.3). There is strong
( f, black arrow), intermediate (blue arrow), and
negative (green arrow) expression of CD1d. Note
the clustering of small lymphocytes with CD1d
positive DDC (black arrow). Scale bar: (a±e) 50 mm;
( f ) 10 mm.
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sections as well as migrated DDC spun down on cytospins were stained
with the APAAP technique as described previously (Nestle et al, 1997).
Unconjugated primary polyclonal antibodies or MoAb, used at 10 mg per
ml (except MoAb 27.1 supernatant at 1:1, MoAb D5 ascitis at 1:250),
are described in Reagents and antibodies.
Immuno¯uorescence Migrated DDC spun down on cytospins were
®xed in acetone, incubated 15 min with normal rabbit serum (Dako
Diagnostic, Switzerland), and stained with anti-CD1d (42.1, IgG1)
followed by goat antimouse conjugated with Texas Red (Southern
Biotechnology Associates) for 1 h. After three washing steps in PBS the
anti-HLA-DR FITC-conjugated MoAb was added for an additional
hour. Afterwards they were washed again, covered with a cover slip, and
analyzed by microscopy (Leica Mikroscopie, Wetzlar, Germany) using
the TCS4D confocal laser scanning system (Leica Lasertechnik,
Heidelberg, Germany).
Flow cytometry analysis All MoAb dilutions and washing steps were
done in PBS containing 2% FBS. 1 3 105 cells per reaction were stained
with the conjugated or unconjugated MoAb described in Reagents and
antibodies followed by a secondary goat antimouse PE or FITC MoAb at
10 mg per ml. In order to block the Fc mediated unspeci®c binding cells
were incubated with FBS and PBS (1:1) for 30 min at 4°C.
To control for nonspeci®c staining the appropriate isotype controls
were used. For single staining cells were labeled with anti-CD1 MoAbs.
To identify dendritic cells cells were double stained with HLA-DR and
CD1 MoAb. All the incubations were done at 4°C for 30 min. The
speci®city of the anti-CD1 MoAb was checked using C1R mock and
C1R CD1d transfectant (kindly provided by Dr. S Balk, Boston) and
C1R CD1a, CD1b, CD1c transfectants (kindly provided by Dr. S.
Porcelli).
Western blot Dermis from microdissected skin sections was boiled in
sodium dodecyl sulfate sample buffer. Equal amounts of proteins were
separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis
and transferred to a nitrocellulose membrane. The Western blot was
developed using D5 as anti-CD1d antibody (gift from Dr. S. Balk,
Boston). C1R mock and C1R CD1d transfectant cell lines (kindly
provided by Dr. S. Balk, Boston) were used as negative and positive
controls, respectively.
Microdissection Cryostat sections were stained with hematoxylin±
eosin and dermis microdissection was performed under light microscope
visualization (magni®cation 2003) using a 30 gauge needle.
RESULTS
Expression of CD1d in normal human skin Immuno-
histochemistry was performed on human skin sections using a
panel of MoAb directed toward different members of the CD1
family. CD1a expression was mostly con®ned to dendritic
appearing cells in the epidermis corresponding to Langerhans cells
(Fig 1a). There were few cells expressing CD1a in dermis. CD1b
and CD1c expression was demonstrated on dendritic cells in
dermis, mostly in a perivascular localization (Fig 1b, c). These cells
correspond to DDC as published previously (Lenz et al, 1993;
Meunier et al, 1993; Nestle et al, 1993). Investigation of CD1d
expression was performed with a panel of six antibodies. Consistent
and equivalent immunohistochemical staining was obtained with
antibodies D5, 51.1.3, and polyclonal rabbit anti-CD1d, which
revealed positive staining on large cells with dendritic processes in
the dermis (Fig 1d). Staining with the MoAb NOR 3.2 revealed
strong staining of keratinocytes as well as a few dendritic cells in
dermis as published previously (Bonish et al, 2000). Most of these
cells were located in the upper dermis in the papillary area and in a
perivascular localization. We did not observe any CD1d expression
on epithelial Langerhans cells. Cytospin preparations from migrated
DDC and Langerhans cells revealed expression of CD1d in various
intensities on DDC (Fig 1e, f) but not Langerhans cells (data not
shown). There were DDC with strong expression (black arrow),
intermediate expression (blue arrow), and no expression (green arrow)
of CD1d.
DDC express CD1d To further investigate the expression of
CD1d on epidermal cells and DDC, cell suspensions were prepared
from normal skin using a cocktail of enzymes as described above
and analyzed by ¯ow cytometry. Double staining with HLA-DR
was performed to identify HLA-DR positive APC. In epidermal
cell suspensions no expression of CD1b or CD1d was observed on
HLA-DR positive cells (data not shown). CD1a and CD1c
expression on HLA-DRbright cells was observed as previously
described (Meunier et al, 1993; data not shown). In fresh dermal
cell suspensions HLA-DR positive cells were found to express
CD1a, CD1b, CD1c, and CD1d (Fig 2a). These cells exhibited
Figure 2. CD1d expression on fresh and migrated DDC. (a) HLA-
DRbright cells express CD1d in fresh dermal cell suspension. Two-color
staining of dermal cell suspension analyzed by ¯ow cytometry shows
different HLA-DR+ cell subsets: CD1a (25% 6 3.6% of the total HLA-
DR+ population), CD1b (16.3% 6 4.0%), CD1c (39.3% 6 3.0%), and
CD1d (16% 6 3.6%). (b) Migrated DDC express CD1d. Two-color
staining of migrated DDC analyzed by ¯ow cytometry: 60.5% 6 8.0%
of DDC were positive for CD1d. (c) Migrated mature CD83 positive
DDC express CD1d.
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high forward and side scatter properties. Three different HLA-DR+
subsets based on their ¯uorescence intensity (bright, medium, dim)
were identi®ed (Fig 2a). Expression of CD1d was observed in the
HLA-DRbright population. Preferential expression of CD1d on the
HLA-DRbright population indicates that CD1d expression in
human dermis is mainly con®ned to activated dendritic cells.
Within HLA-DR positive cells, the mean percentage of CD1
expression was calculated from three independent experiments:
CD1a, 25% 6 3.6%; CD1b, 16.3% 6 4.0%; CD1c, 39.3% 6
3.0%; and CD1d, 16% 6 3.6%. A 2 d culture of fresh cell
suspensions in complete medium with GM-CSF and IL-4 to
induce maturation of dendritic cells did not change the percentages
of CD1 positive cells (data not shown).
To investigate CD1d expression on highly enriched dermal
APC, cells migrating out of dermal fragments after 2 d culture were
analyzed. DDC represented 70%±80% of the total population after
metrizamide enrichment. These cells were highly HLA-DR
positive and expressed CD83 (Fig 2c), a marker of mature
dendritic cells, as well as high levels of CD80 and CD86 (Nestle
et al, 1993).
HLA-DRbright cells coexpressed CD1b and CD1c. CD1d
expression was found on 60.5% 6 8.0% of HLA-DRbright cells
(Fig 2b). Therefore, mature DDC express both classical MHC and
nonclassical CD1 antigen-presenting molecules.
CD1d colocalizes with HLA-DR containing cellular
compartments To get an insight into the cellular distribution
of CD1d molecules two-color immuno¯uoresence was performed
on highly enriched DDC, obtained after migration out of dermal
fragments. Cells were double stained with MoAb against HLA-DR
and CD1d (42.1 MoAb) and were analyzed by confocal laser
scanning microscopy. Strong expression of HLA-DR was observed
on DDC, with HLA-DR containing compartments mostly
localized close to or on the cell surface (Fig 3a). Staining with
anti-CD1d MoAb revealed a subset of cells that were CD1d
positive (Fig 3b). Colocalization of CD1d and HLA-DR (orange/
yellow spots) was observed in compartments close to as well as on
the cell surface (Fig 3c, d).
Microdissected dermis contains a high molecular weight
CD1d variant To further investigate the biochemical nature of
CD1d expressed on dermal APC, Western blotting was performed
on microdissected normal human dermis. CD1d protein was
detected with antibody D5. CD1d in dermis was detected at a
molecular weight of 50±55 kDa. This might be indicative of a
highly glycosylated variant present in human dermis in the absence
of a low or unglycosylated form as found in intestinal epithelium
(Somnay Wadgaonkar et al, 1999). The corresponding band of the
CD1d positive control cell line C1R CD1d was detected at
37 kDa, and appeared unglycosylated (Fig 4).
CD1d is expressed on immature and mature mo-DC As a
next step we investigated the expression of CD1 molecules on mo-
DC. These cells correspond to DDC in vivo (Grassi et al, 1998) and
are currently the favored in vitro study system that allows a
discrimination between immature and mature dendritic cells
(Banchereau et al, 2000). Furthermore they are increasingly used
for immunotherapy of cancer. Therefore, CD1 expression in these
cells might be of potential signi®cance for basic research as well as
clinical applications. Cells were cultured under FBS-free conditions
using 1% AP as used in current clinical trials of dendritic cell
vaccination. Under these conditions CD1a expression on immature
and mature dendritic cells was weak to absent (Fig 5). CD1b and
CD1c expression was upregulated during in vitro differentiation
from monocytes (Fig 5). There was stable and equivalent
expression of these molecules on immature (D6) and mature
dendritic cells (D7 after addition of the maturation cocktail). Only
few data are available on CD1d expression in human APC.
Expression of CD1d was observed on monocytes as well as on mo-
DC (Fig 5). The mean ¯uorescence of mo-DC reached the highest
level around day 4. Immature as well as mature dendritic cells
Figure 3. HLA-DR and CD1d molecules are colocalized in the same cellular compartments. Immuno¯uorescence staining of DDC analyzed
by confocal laser scanning microscopy: (a) HLA-DR-FITC; (b) CD1d-Texas Red (42.1); and (c, d) double staining. Arrows show double positive cells
(c, yellow/orange). Note at higher magni®cation the colocalization of HLA-DR and CD1d represented by yellow/orange spots (d). Scale bars: 10 mm.
Figure 4. A high molecular variant of CD1d is present in human
dermis. Western blot analysis of microdissected dermal sections using
CD1d antibody (D5). C1R mock (±) and C1R CD1d transfectants (+)
were used as negative and positive controls. A, B, C indicate different
dermal samples. Note the presence of a CD1d molecule with apparent
molecular weight 50±55 kDa.
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expressed CD1d molecules indicating that the expression was not
maturation dependent.
CD1d expression is downregulated in the presence of
FBS Earlier studies on mo-DC including dendritic cell
vaccination for patient treatment were performed in the presence
of 10% FBS (Cella et al, 1997; Nestle et al, 1998). Recently, FBS-
free culture conditions using 1% AP were introduced (Thurner et al,
1999). Mo-DC coming from the same patient were generated
using AP or FBS as addition to the culture medium. CD1b and
CD1c were expressed with the same pattern in both AP- and FBS-
treated mo-DC (data not shown). In certain donors expression of
CD1a was observed already in the starting population (day 0
monocytes). In contrast to mo-DC generated in AP, FBS-derived
mo-DC expressed high levels of CD1a. The reverse was true for
CD1d expression. Whereas mo-DC cultured in AP expressed high
levels of CD1d, there was an important downregulation of CD1d
during culture in FBS and in some cases it was completely absent
on mature CD83-positive dendritic cells (Fig 6). In conclusion
there is a strong dependence of CD1 expression on dendritic cell
culture conditions.
DISCUSSION
The CD1 family of antigen-presenting molecules plays an import-
ant role in lipid antigen presentation as well as immune response to
mycobacteria and tumors (Porcelli et al, 1998). In this study we
focused on CD1d, a recently described member of this family, and
show that CD1d expression in skin is largely restricted to dendritic
appearing APC in dermis (DDC) apart from expression on
keratinocytes in epidermis (Bonish et al, 2000). For comparison,
we con®rmed previous studies using an expanded panel of
antibodies, demonstrating CD1a expression mostly on epidermal
Langerhans cells, whereas CD1c was found on DDC (Figs 1, 2)
(Lenz et al, 1993; Meunier et al, 1993; Nestle et al, 1993; Larregina
et al, 1997). Expression of CD1b on DDC was detectable with two
different antibodies. CD1d was found to be mainly expressed on
16% 6 3.6% of HLA-DRbright cells in dermal cell suspensions, but
was clearly absent on HLA-DRbright cells in epidermal cell
suspensions. 60.5% 6 8.0% of cells expressed CD1d in highly
enriched DDC, whereas CD1d expression was absent on
Langerhans cells (Fig 2). The fact that a distinct subpopulation of
DDC expresses CD1d is in strong support of the hypothesis that
there are phenotypically distinct subsets of DDC with otherwise
homogeneous microscopic appearance and expression of adhesion,
costimulatory, and HLA-DR molecules (Meunier et al, 1993;
Nestle et al, 1993; Nestle and Burg, 1999). Interestingly, expression
of all known members of the CD1 family was observed on DDC.
This may be an advantage in the generation of immune response
against tumor antigens or infectious agents such as mycobacteria.
Mycobacterial antigens and glycolipids thereof have been shown to
access distinct CD1 molecules at different intracellular sites
(Schaible et al, 2000). DDC subsets, as de®ned by differential
expression of CD1 molecules, might play a distinct role in skin
immune response.
To get an insight into the cellular and subcellular distribution on
DDC, CD1d was analyzed by confocal laser scanning microscopy.
CD1d mostly colocalized to compartments that contained HLA-
DR molecules (Fig 3). These ®ndings might suggest a common
pathway for classical MHC-related and nonclassical CD1-related
antigen presentation. Microdissected dermis contained CD1d with
a molecular weight of 50±55 kDa (Fig 4), indicating the presence
of a glycosylated form of CD1d. Glycosylation is often considered
to stabilize proteins and might allow for sustained expression of
CD1d and prolonged presentation of CD1d-related antigens in
human skin.
CD1d expression in skin is of potential interest for skin biology
as it is involved in the presentation of glycolipids to natural killer T
cells. It has been shown that a-galactosylceramide, a synthetic
acylphytosphingolipid originally isolated from a marine sponge, is
presented by CD1d to the clonotypic va24/vb11 T cell receptor of
Figure 5. CD1 expression on mo-DC
generated in the presence of AP. Monocytes
were cultured in the presence of IL-4 and GM-
CSF for 6 d in 1% AP. At day 6 they were
stimulated with a maturation cocktail containing
IL-6, TNF-a, and IL-1b for 24 h. At days 0, 2,
4, 6, and 7 cells were analyzed for CD1 molecule
expression. Values represent the mean ¯uores-
cence. Mo-DC generated in AP display a low
level of CD1a expression, whereas CD1b and
CD1c molecules are strongly upregulated during
maturation. CD1d is constantly expressed during
culture.
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natural killer T cells. Such cells were shown to have potent
antitumor activity (Kawano et al, 1999) and also to induce strong
TH-1 bias in autoimmune diseases such as diabetes mellitus (Wilson
et al, 1998). Self glycolipids might represent potential autoantigens
(Shamshiev et al, 1999). Human epidermis is rich in lipids and
glycolipids (Wertz, 1992). A disturbance in lipid production might
lead to aberrant presentation of lipids and glycolipids by CD1d
molecules in in¯ammatory and neoplastic skin conditions. CD1d
expression has been demonstrated on psoriatic KC using the anti-
CD1d antibody NOR3.2 (Nickoloff et al, 1999; Bonish et al,
2000). This antibody might not always meet stringent staining
criteria, however (Yong-Jun Liu, Stanford University, personal
communication), or might recognize different CD1d epitopes
compared to other available anti-CD1d antibodies. Here we have
shown with a panel of anti-CD1d antibodies unequivocal expres-
sion on DDC. Therefore, expression of CD1d by keratinocytes and
professional APC in human dermis might have implications for
autoimmune type chronic in¯ammatory skin diseases, such as
psoriasis.
Mo-DC are currently the preferred in vitro study system for
dendritic cells. They resemble DDC in phenotype and function
(Grassi et al, 1998). Mo-DC may be generated in large numbers
from peripheral blood. They allow the investigation of the impact
of maturation stimuli on dendritic cell biology. Furthermore, these
cells are increasingly used for the immunotherapy of cancers such as
melanoma (Nestle et al, 1999). We detected CD1d expression on
monocytes and both mature and immature mo-DC cultivated in
the presence of AP (Fig 5). In contrast, when AP was replaced by
FBS a downregulation of CD1d during the differentiation and
maturation process was observed, whereas CD1a was strongly
expressed (Fig 6). Differential expression of CD1 molecules on
dendritic cell preparations used for immunotherapy of cancer might
have implications for the repertoire of T cells expanded during the
vaccination process.
In conclusion we have shown that CD1d reactivity in human
dermis is con®ned to dermal dendritic APC in vivo and in vitro.
CD1d in dermis is highly glycosylated and colocalizes with HLA-
DR containing cellular compartments. Expression of CD1d on
mo-DC used for immunotherapy depends on culture conditions
but not on maturation stage.
Expression of CD1d on dermal APC might have implications for
presentation of lipids and glycolipids to effector T cells with
potential relevance for autoimmune and anticancer immune
response in skin.
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Figure 6. CD1d expression is downregulated in the presence of FBS. Effects of FBS versus AP on CD1a and CD1d expression were evaluated.
Mo-DC cultured in FBS upregulate CD1a expression whereas CD1d expression is downregulated. Addition of AP instead of FBS to the culture
medium leads to low or undetectable CD1a expression on mo-DC, whereas CD1d expression is detectable throughout the culture period.
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